• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中枢神经系统不良事件在艺术过程中的可逆性。

Reversibility of Central Nervous System Adverse Events in Course of Art.

机构信息

Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, 16132 Genoa, Italy.

Unit of Infectious Diseases, "Divisione A", Amedeo di Savoia Hospital, 10149 Torino, Italy.

出版信息

Viruses. 2022 May 11;14(5):1028. doi: 10.3390/v14051028.

DOI:10.3390/v14051028
PMID:35632768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9147522/
Abstract

The purpose of this study is to evaluate the frequency of central nervous system adverse events (CNS-AE) on dolutegravir (DTG) and non-DTG containing ART, and their reversibility, in the observational prospective SCOLTA cohort. Factors associated with CNS-AE were estimated using a Cox proportional-hazards model. 4939 people living with HIV (PLWH) were enrolled in DTG (n = 1179) and non-DTG (n = 3760) cohorts. Sixty-six SNC-AE leading to ART discontinuation were reported, 39/1179 (3.3%) in DTG and 27/3760 (0.7%) in non-DTG cohort. PLWH naïve to ART, with higher CD4 + T count and with psychiatric disorders were more likely to develop a CNS-AE. The risk was lower in non-DTG than DTG-cohort (aHR 0.33, 95% CI 0.19−0.55, p < 0.0001). One-year follow-up was available for 63/66 PLWH with CNS-AE. AE resolution was reported in 35/39 and 23/24 cases in DTG and non-DTG cohorts, respectively. The probability of AE reversibility was not different based on ART class, sex, ethnicity, CDC stage, or baseline psychiatric disorder. At the same time, a lower rate of event resolution was found in PLWH older than 50 years (p = 0.017). In conclusion, CNS-AE leading to ART discontinuation was more frequent in DTG than non-DTG treated PLWH. Most CNS-AE resolved after ART switch, similarly in both DTG and non-DTG cohorts.

摘要

本研究旨在评估含多替拉韦(DTG)和不含 DTG 的 ART 方案中,中枢神经系统不良事件(CNS-AE)的发生频率及其可逆性。采用 Cox 比例风险模型评估与 CNS-AE 相关的因素。共有 4939 名 HIV 感染者(PLWH)入组 DTG(n=1179)和非 DTG(n=3760)队列。共报告了 66 例导致 ART 停药的 SNC-AE,DTG 组 39/1179(3.3%),非 DTG 组 27/3760(0.7%)。ART 初治、CD4 + T 计数较高和患有精神障碍的 PLWH 更易发生 CNS-AE。与 DTG 组相比,非 DTG 组的风险较低(aHR 0.33,95%CI 0.19-0.55,p<0.0001)。66 例 CNS-AE 患者中有 63 例可进行 1 年随访。在 DTG 和非 DTG 组中,分别有 35/39 和 23/24 例 CNS-AE 得到缓解。ART 种类、性别、种族、CDC 分期或基线精神障碍与 CNS-AE 逆转概率无差异。同时,发现年龄大于 50 岁的 PLWH 中 CNS-AE 缓解率较低(p=0.017)。综上,DTG 治疗的 PLWH 中 CNS-AE 较非 DTG 治疗的更常见。大多数 CNS-AE 在 ART 转换后得到缓解,在 DTG 和非 DTG 组中相似。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a9f/9147522/7d51746573fd/viruses-14-01028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a9f/9147522/7d51746573fd/viruses-14-01028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a9f/9147522/7d51746573fd/viruses-14-01028-g001.jpg

相似文献

1
Reversibility of Central Nervous System Adverse Events in Course of Art.中枢神经系统不良事件在艺术过程中的可逆性。
Viruses. 2022 May 11;14(5):1028. doi: 10.3390/v14051028.
2
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.基于多替拉韦的方案的持久性:一项为期 5 年的前瞻性观察研究。
AIDS Patient Care STDS. 2021 Sep;35(9):342-353. doi: 10.1089/apc.2021.0089.
3
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.基于多替拉韦的方案在晚期 HIV 初治患者中的疗效和安全性:一项多中心队列研究的结果。
Antiviral Res. 2019 Sep;169:104552. doi: 10.1016/j.antiviral.2019.104552. Epub 2019 Jul 5.
4
A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.中国南京地区初治的晚期 HIV 感染患者中,多替拉韦与依非韦伦方案的回顾性临床研究。
Front Immunol. 2023 Jan 9;13:1033098. doi: 10.3389/fimmu.2022.1033098. eCollection 2022.
5
Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study.初治抗逆转录病毒治疗个体启动多替拉韦、埃替拉韦、拉替拉韦或达芦那韦后的病毒学转归:一项观察性研究
Infect Dis Ther. 2020 Mar;9(1):41-52. doi: 10.1007/s40121-019-00274-5. Epub 2019 Nov 7.
6
Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.多替拉韦/阿巴卡韦/拉米夫定单片方案在 HIV-1 成人感染患者真实队列中的疗效、安全性和成本。
Ann Pharmacother. 2020 Jul;54(7):633-643. doi: 10.1177/1060028019896638. Epub 2020 Jan 8.
7
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.多替拉韦/阿巴卡韦/拉米夫定与当前抗逆转录病毒疗法用于病毒学抑制患者的比较(STRIIVING):一项48周的随机、非劣效性、开放标签的IIIb期研究。
Antivir Ther. 2017;22(4):295-305. doi: 10.3851/IMP3166. Epub 2017 Apr 12.
8
Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.在初治 HIV-1 感染者中,与常见核心药物相比,多替拉韦的疗效和安全性:系统评价和网络荟萃分析。
BMC Infect Dis. 2019 May 30;19(1):484. doi: 10.1186/s12879-019-3975-6.
9
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.多替拉韦:初治整合酶抑制剂患者的临床及实验室安全性
HIV Clin Trials. 2014 Sep-Oct;15(5):199-208. doi: 10.1310/hct1505-199.
10
Dolutegravir Population Pharmacokinetics in a Real-Life Cohort of People Living With HIV Infection: A Covariate Analysis.多替拉韦人群药代动力学在现实生活中 HIV 感染人群中的研究:协变量分析。
Ther Drug Monit. 2019 Aug;41(4):444-451. doi: 10.1097/FTD.0000000000000618.

引用本文的文献

1
Sex differences in discontinuations due to side effects of second-generation integrase strand transfer inhibitors: a systematic review and meta-analysis.第二代整合酶链转移抑制剂副作用导致停药的性别差异:一项系统评价和荟萃分析。
EClinicalMedicine. 2025 May 20;84:103246. doi: 10.1016/j.eclinm.2025.103246. eCollection 2025 Jun.
2
Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial.从多替拉韦/阿巴卡韦/拉米夫定转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺后自我报告的神经精神症状演变:随机DOBINEuro试验的结果
Infect Dis Ther. 2025 Jan;14(1):293-304. doi: 10.1007/s40121-024-01083-1. Epub 2024 Nov 29.
3

本文引用的文献

1
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.基于多替拉韦的方案的持久性:一项为期 5 年的前瞻性观察研究。
AIDS Patient Care STDS. 2021 Sep;35(9):342-353. doi: 10.1089/apc.2021.0089.
2
Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.在生理相关浓度下,度鲁特韦、恩曲他滨和依非韦伦会引起 HeLa 上皮细胞和 BV2 小胶质细胞发生不同的代谢改变。
Front Immunol. 2021 May 20;12:639378. doi: 10.3389/fimmu.2021.639378. eCollection 2021.
3
Redefining therapeutic success in HIV patients: an expert view.
Reversibility of Neuropsychiatric Adverse Events after Switching to Darunavir/Cobicistat or Doravirine in Men on INSTI-Based Regimen.基于 INSTI 方案的男性换用达芦那韦/考比司他或多伟拉韦后神经精神不良事件的逆转。
Viruses. 2024 Jul 5;16(7):1083. doi: 10.3390/v16071083.
4
Central nervous system and neuropsychiatric disturbances in people living with HIV.HIV感染者的中枢神经系统和神经精神障碍
Infez Med. 2023 Dec 1;31(4):488-494. doi: 10.53854/liim-3104-7. eCollection 2023.
5
Prevalence and Risk Factors for Poor Sleep Quality in People Living with HIV: Preliminary Observations from an HIV Outpatient Clinic.HIV 感染者睡眠质量差的患病率及相关因素:HIV 门诊初步观察。
Viruses. 2023 Aug 10;15(8):1715. doi: 10.3390/v15081715.
6
Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies.使用度鲁特韦后的中枢神经系统疾病:来自临床前和临床研究的证据。
Pharmacol Rep. 2023 Oct;75(5):1138-1151. doi: 10.1007/s43440-023-00515-y. Epub 2023 Aug 21.
7
Trajectories of CD4/CD8 T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study.换用多替拉韦为基础的二联方案治疗 96 周后 CD4/CD8 T 细胞比值的变化轨迹:一项多中心前瞻性队列研究的结果。
Viruses. 2022 Oct 22;14(11):2315. doi: 10.3390/v14112315.
重新定义 HIV 患者的治疗成功:专家观点。
J Antimicrob Chemother. 2021 Sep 15;76(10):2501-2518. doi: 10.1093/jac/dkab168.
4
Mini-review: Elucidating the psychological, physical, and sex-based interactions between HIV infection and stress.综述:阐明 HIV 感染与压力之间的心理、生理和性别交互作用。
Neurosci Lett. 2021 Mar 16;747:135698. doi: 10.1016/j.neulet.2021.135698. Epub 2021 Feb 1.
5
Burden of living with HIV among men who have sex with men: a mixed-methods study.男男性行为者中 HIV 感染者的生活负担:一项混合方法研究。
Lancet HIV. 2020 Dec;7(12):e835-e843. doi: 10.1016/S2352-3018(20)30197-1. Epub 2020 Oct 8.
6
Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV.老年人与 HIV 感染者血浆和脑脊液中更高的度鲁特韦暴露相关。
Clin Pharmacokinet. 2021 Jan;60(1):103-109. doi: 10.1007/s40262-020-00916-9.
7
Factors Associated With Weight Gain in People Treated With Dolutegravir.多替拉韦治疗人群中与体重增加相关的因素
Open Forum Infect Dis. 2020 May 26;7(6):ofaa195. doi: 10.1093/ofid/ofaa195. eCollection 2020 Jun.
8
Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.在比利时的一个 4101 名 HIV 患者队列中,基于多替拉韦的抗逆转录病毒疗法在真实环境中的疗效。
AIDS. 2020 Jul 1;34(8):1151-1159. doi: 10.1097/QAD.0000000000002533.
9
Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.临床实践中比克替拉韦联合恩曲他滨/替诺福韦艾拉酚胺的短期神经精神耐受性
Antivir Ther. 2020;25(2):83-90. doi: 10.3851/IMP3351.
10
Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice.度鲁特韦在真实临床实践中的神经精神不良影响。
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Feb;39(2):78-82. doi: 10.1016/j.eimc.2020.02.018. Epub 2020 Mar 28.